BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that the Company will participate in the following two investor events in May:
- Deutsche Bank 44th Annual Health Care Conference on Tuesday, May 7, 2019 at The InterContinental Hotel in Boston.
- Singular Research Spring Select Web Call on Thursday, May 30, 2019.
A live audio webcast of the Singular Research Spring Select Web Call may be accessed via the "Investor Relations" section of Anika’s website at www.anikatherapeutics.com. An audio archive of the presentation also will be available on the website.
About Anika Therapeutics, Inc.
Anika
Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated
orthopedic and regenerative medicines company based in Bedford,
Massachusetts. Anika is committed to improving the lives of patients
with degenerative orthopedic diseases and traumatic conditions with
clinically meaningful therapies along the continuum of care, from
palliative pain management to regenerative tissue repair. The Company
has over two decades of global expertise developing, manufacturing, and
commercializing more than 20 products based on its proprietary hyaluronic
acid (HA) technology. Anika's orthopedic medicine portfolio
includes ORTHOVISC®, MONOVISC®,
and CINGAL®,
which alleviate pain and restore joint function by replenishing depleted
HA, and HYALOFAST,
a solid HA-based scaffold to aid cartilage repair and regeneration. For
more information about Anika, please visit www.anikatherapeutics.com.
